ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.

“Some of the most worrying shortages involve generic sterile injectable medications, including cancer chemotherapy drugs and emergency medications stored in hospital crash carts and procedural areas,” said ASHP CEO Paul Abramowitz.

In a statement submitted to the House Ways and Means Committee for a February hearing on chronic drug shortages, AHA recommended Congress enact legislation to diversify manufacturing sites and sources for critical pharmaceutical ingredients; support an increase in end-user and supply chain inventories for critical medications; develop a rating system for drug maker quality management processes; identify essential drugs needing more domestic manufacturing capacity; and require drug makers to disclose where their products are made and when demand for essential drugs spikes. 
 

Related News Articles

Headline
The Department of Health and Human Services Sept. 30 released a statement on the dockworker strike at ports along the East and Gulf coasts, saying that…
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…
Headline
The AHA sent a letter June 28 to the U.S. Trade Representative responding to a proposed increase in Section 301 tariffs for goods produced in China, which…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…